Spruce Biosciences is a clinical-stage biopharmaceutical development enterprise that was founded with the core mission of researching, developing, and commercializing novel therapeutics for rare endocrine, neurological, and metabolic disorders where significant unmet medical needs exist. The company's principal therapeutic development program historically centered on tildacerfont, an oral, non-steroidal, highly selective small-molecule antagonist of the corticotropin-releasing factor type 1 (CRF1) receptor, engineered to treat conditions like classic Congenital Adrenal Hyperplasia (CAH), Polycystic Ovary Syndrome (PCOS), and Major Depressive Disorder (MDD) by regulating excessive adrenocorticotropic hormone (ACTH) production. To expand and diversify its therapeutic pipeline, Spruce Biosciences also acquired and advanced developmental programs in the lysosomal storage disease space, notably focusing on Tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B), driving translational research through clinical trials and regulatory engagement.